Citius Oncology (NASDAQ:CTOR – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports.
Citius Oncology Stock Down 2.3 %
NASDAQ CTOR opened at $1.25 on Friday. The company has a current ratio of 0.34, a quick ratio of 0.08 and a debt-to-equity ratio of 0.08. Citius Oncology has a 52 week low of $0.85 and a 52 week high of $49.00. The firm’s 50-day simple moving average is $1.17.
Analysts Set New Price Targets
Separately, Maxim Group began coverage on Citius Oncology in a research report on Wednesday, November 27th. They issued a “buy” rating and a $3.00 target price for the company.
Citius Oncology Company Profile
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Citius Oncology
- About the Markup Calculator
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- Investing in Construction Stocks
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- How is Compound Interest Calculated?
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
